Dr. Richard Ambinder, MD

Dr. Ambinder practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Ambinder's NPI, 1528022407, was assigned on April 17, 2006. Dr. Ambinder graduated from The Johns Hopkins University School of Medicine in 1979. Dr. Ambinder holds Maryland license D23887.

Dr. Ambinder's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Ambinder's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Ambinder is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Ambinder to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ambinder practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Ambinder's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Ambinder is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Ambinder's licenses on file in 4 states: Maryland, Virginia, Pennsylvania and Michigan.

Dmand AI lists chronic leukemia, colorectal cancer, lymphoma and multiple myeloma among the conditions Dr. Ambinder treats.

CMS data shows 328 Medicare services from Dr. Ambinder across 5 procedure codes in 2024, for 133 Medicare patients. Medicare paid $23,282 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 133 Medicare patients who saw Dr. Ambinder in 2024. The largest group is 65 to 74, with 71 patients. 72% of them have high cholesterol, and 68% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ambinder's median patient age at 72, with 40% women.

In 2024, Dr. Ambinder wrote 159 Medicare Part D claims for 25 patients. 57% of them were for generic drugs. CMS names the drug for 104 of them, across 6 drugs with 11 or more claims each, at $908,495 in total drug cost. In 2023, CMS named 166 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Ambinder for performance year 2024, reported as part of a group. CMS lists Dr. Ambinder as offering telehealth.

Dmand AI links 288 papers to Dr. Ambinder, published from 2005 to 2025. 2017 was the busiest year, with 19. The most frequent topics are Herpesvirus 4, Human, Cyclophosphamide and Hodgkin Disease. Dr. Ambinder has published most often in Biol Blood Marrow Transplant. Dr. Ambinder's most frequent co-authors are Leonido Luznik, MD, Carol Ann Huff, MD and Robert A. Brodsky, MD.

Dmand AI links Dr. Ambinder to 14 clinical trials, 4 of them phase 1/2 studies. 3 are still active or recruiting. Conditions studied include Lymphoma, Primary Effusion, Sarcoma, Kaposi and Lymphoma. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors the most, 5.

CMS Open Payments shows 1 general payment to Dr. Ambinder from 1 drug or device company in 2017. Consulting fees make up the largest share, 100% of the total. Celgene Corporation paid the most, $1,500.

Dmand AI lists 7 awards for Dr. Ambinder, most recently America's Top Doctors in 2014.

Dr. Ambinder graduated from The Johns Hopkins University School of Medicine in 1979.

Dr. Ambinder is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.